614 related articles for article (PubMed ID: 28514746)
1. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
2. Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion.
Shan Y; Ding H; Lu J; Ge Z; Tan Y
Oncotarget; 2017 Dec; 8(68):112809-112815. PubMed ID: 29348867
[TBL] [Abstract][Full Text] [Related]
3. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer.
Wang Y; Chen Z; Chen J; Pan J; Zhang W; Pan Q; Ding H; Lin X; Wen X; Li Y; Meng QH
Clin Chim Acta; 2013 Jun; 421():230-5. PubMed ID: 23523589
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion.
Yang J; Zhu Y; Wu L; Zhu W; Zhang X; Yang Y; Xu C
Clin Respir J; 2018 Jan; 12(1):279-284. PubMed ID: 27402224
[TBL] [Abstract][Full Text] [Related]
6. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.
Zhang F; Wang J; Zheng X; Hu L; Chen J; Jiang F; Wang Y
J Clin Lab Anal; 2018 Oct; 32(8):e22576. PubMed ID: 29797475
[TBL] [Abstract][Full Text] [Related]
10. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.
Zhu J; Feng M; Liang L; Zeng N; Wan C; Yang T; Shen Y; Wen F
BMC Cancer; 2017 Aug; 17(1):590. PubMed ID: 28854885
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
12. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.
Zhang F; Wang J; Fu J; Hu L; Zheng X; Wang Y; Chen B
J Clin Lab Anal; 2020 Mar; 34(3):e23091. PubMed ID: 31709646
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
15. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis.
Tian P; Shen Y; Feng M; Zhu J; Song H; Wan C; Chen L; Wen F
Postgrad Med; 2015 Jun; 127(5):529-34. PubMed ID: 25979108
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.
Jing X; Wei F; Li J; Dai L; Wang X; Jia L; Wang H; An L; Yang Y; Zhang G; Cheng Z
Clin Respir J; 2018 Mar; 12(3):986-990. PubMed ID: 28127951
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
19. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.
Xu C; Yu L; Zhan P; Zhang Y
Eur J Med Res; 2014 May; 19(1):23. PubMed ID: 24887477
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
